Life Science Nation Newsletter  |  August 27, 2015  |  Issue 126

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Aug. 20 - Aug. 26)
Seeking Preclinical Biologic Opportunities
Seeking Partnerships in Cardio, Oncology, Virology and More
Seeking Global Biopharmaceutical, Medtech, and Diagnostic Opportunities
Seeking to Make First Venture Investments
In This Issue
What Does It Take to Get a Meeting: The Targeted Outreach Curve
       READ MORE
Double Panel Announcement: Medtech and Biotech Angels

LSN Summer Reading Series, Chapter 14: "Thirty-One Tips for Effective Fundraising"

LSN Videos
Video Recap of [email protected] 2015

[email protected] Investor Panel Videos

LSN in the News
What Does It Take to Get a Meeting: The Targeted Outreach Curve
By Lucy Parkinson, Senior Research Manager, LSN    

Earlier this month, we covered the benefits of using CRM to organize your fundraising campaign. By logging every contact, you can collect useful data points that will map your campaign's progress. LSN's advisory arm, Boston Innovation Capital, logs every call made and every email sent during the course of a fundraising campaign in a CRM system. Using data from a current BIC project, we'll take a look at what it typically takes for a company to get a meeting.

Using the LSN Investor Platform, BIC generated a list of over 250 investors from around the globe as strong potential fits for the company (a US-based medical device developer). The outreach team designed a concise email pitch and a phone message, and performed outreach to all of the investors on the GTL. Thus far, this outreach has generated meetings with 31 investment and strategic firms. But how many outreach attempts did it take to generate a positive response from each investor? As we store all this information in the campaign Salesforce account, it's easy for us to dive in there and take a look at the road we've travelled...

Double Panel Announcement: Medtech and Biotech Angels
By Shaoyu Chang, MD, MPH, Senior Research Analyst, LSN

Angel investors are some of the earliest and most important allies for entrepreneurs. They supply early stage companies with the much needed capital along with their sector expertise, business acumen, and professional network.

We have seen a growing trend of angels syndicating and participating in larger deals. Angel investment round sizes increased sharply in 2014. The healthcare sector showed the largest growth, where the median angel round reached $2 million, up from $1.57 million in 2013. However each angel group comes with unique membership composition, professional knowledge, and investment focus. It is an often daunting task for a scientist entrepreneur to identify and build relationship with the right angel who will move their new ideas forward.

LSN have gathered the most prominent angel groups in life sciences for two panel sessions to be held simultaneously at RESI Boston: Biotech Angels and Medtech Angels.

The Biotech Angels Panel will be focused on current trends in angel investment in the biopharmaceutical field. The panel will be moderated by Pravin Chaturvedi from TIE Angels, and will hear from:
  • Jennifer Seibert, CEO, GAP Ventures
  • Mic Williams, President, Boston Harbor Angels
  • Richard Anders, Co-Managing Director at Mass Medical Angels
  • Jeffrey Arnold, Member, Boston Harbor Angels & Mass Medical Angels
The Medtech Angels Panel will discuss trends in angel investment in medical technologies including devices, diagnostics, and smart devices. The panel will be moderated by Steve Goodman, Co-Founder at Mid Atlantic Bio Angels, and will hear from:
  • David Verrill, Founder & Managing Director, Hub Angels Investment Group
  • Michael Harsh, Limited Partner, Golden Angels Investors
  • Patricia Gray, Member, Mass Medical Angels
  • Richard Yules, Vice President, New World Angels
These sessions will help scientist entrepreneurs to better understand the perspective of an angel. What types of deals are most attractive to each angel? Who is the right group for my technology and how to initiate a dialogue with them? What to expect in the due diligence process? For early stage entrepreneurs considering angel capital, this is an excellent opportunity to meet them face-to-face.

LSN Summer Reading Series, Chapter 14: "Thirty-One Tips for Effective Fundraising"
By Michael Quigley, Director of Research, LSN

To bring LSN's Life Science Executive's Fundraising Manifesto toward a close, we provide some motivational advice and tactical reminders to help a fundraising CEO bring their outbound campaign to a successful resolution.

With illustrations and helpful mottos, this 'cheat sheet' chapter will help the reader find their way through the fundraising maze in good spirits. From how to stay optimistic during the tough times, to when to stop marketing to investors, this chapter has it covered.